Fennec Pharmaceuticals
(NASDAQ) FENC
Fennec Pharmaceuticals Financials at a Glance
Market Cap
$364.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$51.00M
Net Income (TTM)
-$8.38M
EPS (TTM)
-$0.30
P/E Ratio
-35.42
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Price
$10.55
Volume
173,137.153
Open
$10.31
Price
$10.55
Volume
173,137.153
Open
$10.31
Previous Close
$10.49
Daily Range
$10.08 - $10.61
52-Week Range
$5.65 - $11.31
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
0.66 (Low)
Price
$10.55
Volume
173,137.153
Open
$10.31
Previous Close
$10.49
Daily Range
$10.08 - $10.61
52-Week Range
$5.65 - $11.31
Estimated Earnings Date
Aug 13, 2026
FENC News
FENC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Fennec Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
35
CEO
Jeffrey S Hackman
Website
www.fennecpharma.comHeadquarters
Research Triangle Park, NC 27709, US
FENC Financials
Key Financial Metrics (TTM)
Gross Margin
92.23%
Operating Margin
-11.04%
Net Income Margin
-16.42%
Return on Equity
-54.75%
Return on Capital
-18.10%
Return on Assets
-11.66%
Earnings Yield
-2.82%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$364.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
34.74M
Volume
173.14K
Avg. Volume
269.72K
Financials (TTM)
Gross Profit
$47.04M
Operating Income
-$5.63M
EBITDA
-$6.67M
Operating Cash Flow
-$5.78M
Capital Expenditure
$0.00
Free Cash Flow
-$5.78M
Cash & ST Invst.
$40.18M
Total Debt
$0.00
Fennec Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$15.11M
+72.6%
Gross Profit
$14.54M
+73.5%
Gross Margin
96.23%
N/A
Market Cap
$364.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$11.39M
N/A
Employees
32
N/A
Net Income
$201.00K
+117.3%
EBITDA
$234.00K
+142.8%
Quarterly Fundamentals
Total Cash
$40.18M
+77.2%
Total Debt
$0.00
-100.0%
Accounts Receivable
$18.76M
+21.5%
Inventory
$1.86M
+32.2%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
N/A
Return on Assets
-11.66%
N/A
Return on Invested Capital
-9.05%
N/A
Free Cash Flow
$2.38M
+155.1%
Operating Cash Flow
$2.38M
+155.1%